CRIS Current Research Information System

ARGNANI, LISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.872
AS - Asia 8.543
EU - Europa 8.306
SA - Sud America 514
Continente sconosciuto - Info sul continente non disponibili 490
AF - Africa 427
OC - Oceania 15
Totale 28.167
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.638
VN - Vietnam 2.388
SG - Singapore 2.345
NL - Olanda 2.163
CN - Cina 1.993
IT - Italia 1.451
DE - Germania 1.105
GB - Regno Unito 1.062
SE - Svezia 935
HK - Hong Kong 621
FR - Francia 375
BR - Brasile 350
IN - India 345
RU - Federazione Russa 328
IE - Irlanda 201
UA - Ucraina 180
KR - Corea 149
BD - Bangladesh 144
JP - Giappone 136
CA - Canada 126
FI - Finlandia 120
ZA - Sudafrica 100
TG - Togo 98
CI - Costa d'Avorio 95
EE - Estonia 77
AR - Argentina 62
JO - Giordania 57
PL - Polonia 54
PH - Filippine 53
ID - Indonesia 50
TH - Thailandia 47
SC - Seychelles 45
AT - Austria 43
NG - Nigeria 39
MX - Messico 38
IQ - Iraq 36
ES - Italia 33
BE - Belgio 32
CH - Svizzera 28
TR - Turchia 26
CO - Colombia 21
IR - Iran 19
TW - Taiwan 19
BG - Bulgaria 18
CL - Cile 18
SA - Arabia Saudita 17
EC - Ecuador 16
PK - Pakistan 15
PY - Paraguay 14
HR - Croazia 13
JM - Giamaica 13
MY - Malesia 13
UZ - Uzbekistan 13
AU - Australia 12
CR - Costa Rica 12
KE - Kenya 12
LT - Lituania 12
RO - Romania 12
GR - Grecia 11
VE - Venezuela 11
PE - Perù 10
EG - Egitto 9
LB - Libano 9
PT - Portogallo 9
CZ - Repubblica Ceca 8
GT - Guatemala 7
MA - Marocco 7
PR - Porto Rico 7
RS - Serbia 7
UY - Uruguay 7
IL - Israele 6
OM - Oman 6
TT - Trinidad e Tobago 6
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
NI - Nicaragua 5
TN - Tunisia 5
BY - Bielorussia 4
ET - Etiopia 4
HU - Ungheria 4
KG - Kirghizistan 4
MD - Moldavia 4
PS - Palestinian Territory 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BO - Bolivia 3
HN - Honduras 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
LC - Santa Lucia 3
NZ - Nuova Zelanda 3
SV - El Salvador 3
BW - Botswana 2
DK - Danimarca 2
DZ - Algeria 2
GE - Georgia 2
GH - Ghana 2
GY - Guiana 2
LK - Sri Lanka 2
LU - Lussemburgo 2
Totale 27.644
Salva come PNG Salva come JPEG
Città #
Singapore 1.618
Eygelshoven 1.296
Ashburn 1.033
Southend 881
Fairfield 746
Kerkrade 667
Chandler 622
Hong Kong 571
San Jose 530
Ho Chi Minh City 528
Santa Clara 503
Houston 459
Hanoi 433
Frankfurt am Main 400
Woodbridge 357
Seattle 336
Wilmington 307
Council Bluffs 306
Beijing 288
Hefei 283
Princeton 280
Dong Ket 253
Ann Arbor 248
Cambridge 244
Bologna 232
Boardman 210
Dublin 201
New York 183
Los Angeles 166
Milan 158
Lauterbourg 142
Seoul 130
Berlin 115
Tokyo 113
Lomé 98
Abidjan 95
Helsinki 95
Dallas 94
Nanjing 94
Westminster 93
Chicago 91
Rome 81
Padova 77
Jacksonville 76
Jinan 76
Buffalo 74
Da Nang 72
Haiphong 69
Bremen 60
São Paulo 58
Amman 57
San Diego 55
Shenyang 52
Phoenix 49
Guangzhou 47
Redondo Beach 47
Turin 45
Changsha 44
Warsaw 42
London 41
Secaucus 40
Shanghai 40
Saint Petersburg 39
Falkenstein 38
Kyiv 37
Toronto 37
The Dalles 36
Tianjin 36
Abeokuta 34
Florence 34
Dearborn 33
Hebei 32
Redmond 32
Zhengzhou 32
Hangzhou 30
Hyderabad 30
Nuremberg 30
Brussels 29
Nanchang 29
Bengaluru 28
Brooklyn 28
Des Moines 28
Jakarta 28
Jiaxing 28
Orem 27
Munich 24
San Francisco 24
Naples 23
Yubileyny 23
Lappeenranta 22
Montreal 22
Redwood City 22
Bangkok 21
Biên Hòa 21
Taizhou 21
Amsterdam 20
Atlanta 20
Medford 20
Olalla 20
Düsseldorf 19
Totale 17.758
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.882
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 488
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 266
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 264
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 259
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 252
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 251
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 249
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 238
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 233
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 233
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 230
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 228
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 227
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 227
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 226
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 225
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 223
Stile di vita e obesità nell’adolescente 219
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 214
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 213
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 213
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 212
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 207
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 204
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 201
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 201
Electrochemotherapy in Vulvar Cancer and Cisplatin Combined with Electroporation. Systematic Review and In Vitro Studies 198
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 196
Chinese Women in Italy. Menarche, Pregnancy and Maternity. 195
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 195
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 193
Relationships between anthropometric parameters and motor tests in young rugby players 189
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 189
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 188
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 188
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 187
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 187
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 186
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study 185
Quality of life with vulvar carcinoma treated with palliative electrochemotherapy: The elechtra (electrochemotherapy vulvar cancer) study 185
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 183
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 182
The Prognostic value of tumor and microenvironment markers in classifical Hodgkin lymphoma (CHL) patients. 181
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 181
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 181
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 180
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 179
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 179
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 178
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 177
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 176
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 174
Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope 173
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 172
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 171
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 171
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 169
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 168
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 167
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 167
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 164
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 163
Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report 163
The prognostic value of biologic markers in classical hodgkin lymphoma (CHL) patients. 163
Growth of Chinese Italian Infants in the first 2 years of life. 162
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: Bridge to transplant 162
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 162
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 161
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 161
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 160
Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma 160
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. 159
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 159
Primary ocular adnexal lymphomas: a retrospective study of 25 patients. 158
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease 158
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 156
Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. 155
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 154
Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report 154
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 153
PET/CT guided biopsy in lymphoma patients 150
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program 148
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 147
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma 147
Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study 147
Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. 146
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab 146
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 145
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 145
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 145
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 144
Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor 144
Body image perception in North Italians from childhood to adulthood . 142
Weight status and body image perception in Italian children. 140
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 140
Body image patterns, self awareness and physical growth. Preliminary notes 139
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 139
Medical students’ attitude toward robotic surgery: time to revise medical school curricula? 137
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 137
Totale 21.170
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.253
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.253
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.974 0 0 0 249 207 114 46 189 80 178 508 403
2022/20232.856 278 417 189 380 218 214 82 226 433 94 182 143
2023/2024927 86 165 77 111 73 117 63 44 30 73 37 51
2024/20253.998 164 510 352 269 652 183 391 124 98 316 149 790
2025/202610.902 645 783 738 554 865 1.785 2.012 237 1.782 791 402 308
2026/20271.575 346 408 762 59 0 0 0 0 0 0 0 0
Totale 28.167